​Bryce Allen, Ph.D. is the co-founder and CEO of Differentiated Therapeutics (dx/tx), a company combining breakthroughs in biophysics, chemoproteomics, molecular simulation, AI, and automation to map the conformational basis of induced proximity and to use that map to design novel degrader therapeutics. Previously, he was the founding Head of Integrated Data Sciences at Silicon Therapeutics and played a key role in building the company from three employees to over one hundred, culminating in its acquisition by Roivant Sciences in 2021, driven in large part by the cutting edge computational platform. During that period he spearheaded the development and application of the computational platform to drug discovery projects. He played a leading role in the discovery and optimization of SNX281, a first-in-class small molecule STING agonist currently in phase I clinical trials, taking the program from an initial AI discovered hit to a clinical candidate in <3 years.